BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2538251)

  • 1. Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell lung cancer.
    Cantwell BM; Veale D; Rivett C; Ghani S; Harris AL
    Cancer Chemother Pharmacol; 1989; 23(4):252-4. PubMed ID: 2538251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study.
    Axelson JA; Clark RH; Dimitrov NV
    Am J Clin Oncol; 1987 Jun; 10(3):243-4. PubMed ID: 3035912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience.
    Albain KS; Swinnen LJ; Erickson LC; Stiff PJ; Fisher SG; Fisher RI
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):102-9. PubMed ID: 1641650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.
    Richards F; Perry DJ; Goutsou M; Modeas C; Muchmore E; Rege V; Chahinian AP; Hirsh V; Poiesz B; Green MR
    Cancer; 1991 Jun; 67(12):2974-9. PubMed ID: 1646066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study.
    Grunberg SM; Crowley JJ; Livingston RB; Muggia FM; MacDonald JS; Williamson SK; Stephens RL
    Cancer Chemother Pharmacol; 1991; 28(3):211-3. PubMed ID: 1649706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
    Nakano T; Ikegami H; Nakamura S; Kawase T; Nishikawa H; Yokota S; Yoshida M; Tachibana T; Igarashi T; Komuta K; Higashino K
    Br J Cancer; 1996 May; 73(9):1096-100. PubMed ID: 8624270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
    Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
    Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
    von Pawel J; Wagner H; Niederle N; Heider A; Koschel G; Hecker D; Hanske M
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):47-50. PubMed ID: 9007121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
    Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
    Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.
    Honda R; Fujita A; Inoue Y; Asakawa M; Suzuki A
    Cancer Chemother Pharmacol; 1990; 26(5):373-6. PubMed ID: 2170045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
    Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
    Shirinian M; Lee JS; Dhingra HH; Greenberg J; Hong WK
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):49-53. PubMed ID: 1329212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer.
    Murray N; Coppin C; Coldman A; Pater J; Rapp E
    J Clin Oncol; 1994 Nov; 12(11):2333-9. PubMed ID: 7964949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group.
    Gandara DR; Perez EA; Wold H; Caggiano V; Malec M; Ahn DK; Meyers F; Carlson RW
    Cancer Chemother Pharmacol; 1990; 27(3):243-7. PubMed ID: 2176134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.